{"id":53951,"date":"2026-01-13T21:11:37","date_gmt":"2026-01-13T13:11:37","guid":{"rendered":"https:\/\/flcube.com\/?p=53951"},"modified":"2026-01-13T21:11:38","modified_gmt":"2026-01-13T13:11:38","slug":"hisoar-pharma-invests-rmb-150-million-in-wanbangdes-wp205-for-als-securing-15-global-revenue-share","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53951","title":{"rendered":"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share"},"content":{"rendered":"\n<p><strong>Zhejiang Hisoar Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002099:SHE\">SHE: 002099<\/a>) announced a strategic collaboration with <strong>Wanbangde New Building Materials Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002082:SHE\">SHE: 002082<\/a>) to co\u2011develop <strong>WP205<\/strong>, a small\u2011molecule cyclic peptide agonist for <strong>amyotrophic lateral sclerosis (ALS)<\/strong> that has received <strong>FDA Orphan Drug Designation<\/strong>. Hisoar will provide <strong>RMB\u202f150\u202fmillion (USD\u202f21.5\u202fmillion)<\/strong> in funding in exchange for <strong>15\u202f% of global commercialization revenue<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Hisoar Pharma (investor) and Wanbangde (originator)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>WP205 (MCR-targeting cyclic peptide)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Amyotrophic lateral sclerosis (ALS)<\/td><\/tr><tr><td><strong>Total Investment<\/strong><\/td><td>RMB\u202f150\u202fmillion (USD\u202f21.5\u202fmillion)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB\u202f120\u202fmillion (USD\u202f17.2\u202fmillion)<\/td><\/tr><tr><td><strong>Milestone Payment<\/strong><\/td><td>RMB\u202f30\u202fmillion (USD\u202f4.3\u202fmillion) upon Phase\u202fIII initiation or conditional approval<\/td><\/tr><tr><td><strong>Revenue Share<\/strong><\/td><td>Hisoar receives <strong>15\u202f% of global net sales<\/strong> post\u2011launch<\/td><\/tr><tr><td><strong>Development Responsibilities<\/strong><\/td><td>Wanbangde leads R&amp;D, regulatory, and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-als-market-landscape\">Drug Profile &amp; ALS Market Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> WP205 is a <strong>small\u2011molecule cyclic peptide agonist<\/strong> targeting melanocortin receptors (MCR), designed to modulate neuroinflammation and motor neuron survival pathways<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> <strong>FDA Orphan Drug Designation<\/strong> granted; qualifies for <strong>7\u2011year market exclusivity<\/strong>, tax credits, and PDUFA fee waivers<\/li>\n\n\n\n<li><strong>Clinical Need:<\/strong> ALS affects <strong>~30,000 patients in the US<\/strong> and <strong>~50,000 in China<\/strong>; median survival is <strong>3\u20115\u202fyears<\/strong> from diagnosis<\/li>\n\n\n\n<li><strong>Current Standards:<\/strong> Generic riluzole and edaravone offer modest benefit; newer agents (Relyvrio, Qalsody) target genetic subtypes only<\/li>\n\n\n\n<li><strong>WP205 Potential:<\/strong> MCR agonism represents a <strong>novel disease\u2011modifying approach<\/strong> with potential for broad ALS population application<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-revenue-forecast\">Market Opportunity &amp; Revenue Forecast<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global ALS Market Size<\/strong><\/td><td>$820\u202fmillion<\/td><td>$950\u202fmillion<\/td><td>$1.15\u202fbillion<\/td><\/tr><tr><td><strong>WP205 Addressable Population<\/strong><\/td><td>75,000<\/td><td>78,000<\/td><td>81,000<\/td><\/tr><tr><td><strong>Peak Market Penetration<\/strong><\/td><td>0\u202f%<\/td><td>5\u202f%<\/td><td>12\u202f%<\/td><\/tr><tr><td><strong>Annual Treatment Cost (USD)<\/strong><\/td><td>\u2013<\/td><td>$125,000<\/td><td>$118,000<\/td><\/tr><tr><td><strong>Peak Global Revenue<\/strong><\/td><td>\u2013<\/td><td>$488\u202fmillion<\/td><td>$1.15\u202fbillion<\/td><\/tr><tr><td><strong>Hisoar\u2019s 15\u202f% Revenue Share<\/strong><\/td><td>\u2013<\/td><td>$73\u202fmillion<\/td><td>$173\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Focus:<\/strong> Wanbangde plans <strong>NDA submission to NMPA<\/strong> in <strong>Q4\u202f2027<\/strong> leveraging domestic orphan drug fast\u2011track<\/li>\n\n\n\n<li><strong>US Pathway:<\/strong> Phase\u202fII trial initiation expected <strong>Q2\u202f2026<\/strong>; potential <strong>breakthrough therapy designation<\/strong> based on preclinical neuroprotective data<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Hisoar\u2019s investment will fund <strong>GMP\u2011compliant peptide synthesis facility<\/strong> in Zhejiang province<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-strategic-positioning\">Competitive Landscape &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Drug<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>AstraZeneca<\/strong><\/td><td>Tofersen<\/td><td>Antisense (SOD1)<\/td><td>Approved<\/td><td>Genetic\u2011specific only<\/td><\/tr><tr><td><strong>Amylyx<\/strong><\/td><td>Relyvrio<\/td><td>Phenylbutyrate\/TAURSO<\/td><td>Approved<\/td><td>Modest efficacy<\/td><\/tr><tr><td><strong>Wanbangde<\/strong><\/td><td><strong>WP205<\/strong><\/td><td>MCR agonist<\/td><td>Phase\u202fII ready<\/td><td>Broad ALS population<\/td><\/tr><tr><td><strong>Biogen<\/strong><\/td><td>BIIB105<\/td><td>ASO (Ataxin\u20112)<\/td><td>Phase\u202fIII<\/td><td>Genetic\u2011specific<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MCR Platform Value:<\/strong> Agreement includes <strong>future collaboration<\/strong> on additional MCR\u2011targeting cyclic peptides for <strong>metabolic and neurodegenerative diseases<\/strong>, expanding Hisoar\u2019s biotech footprint<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Orphan drug designation and unmet need provide <strong>high probability of regulatory success<\/strong> and premium pricing<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding WP205 development timelines, revenue forecasts, and global commercialization. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory approval processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u6d77\u7fd4\u836f\u4e1a\uff1a\u5173\u4e8e\u7b7e\u8ba2\u521b\u65b0\u836f\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6d77\u7fd4\u836f\u4e1a\uff1a\u5173\u4e8e\u7b7e\u8ba2\u521b\u65b0\u836f\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-f5c97489-4eb2-4e1c-84ad-a44aee2e500c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u6d77\u7fd4\u836f\u4e1a\uff1a\u5173\u4e8e\u7b7e\u8ba2\u521b\u65b0\u836f\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\">\u6d77\u7fd4\u836f\u4e1a\uff1a\u5173\u4e8e\u7b7e\u8ba2\u521b\u65b0\u836f\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u6d77\u7fd4\u836f\u4e1a\uff1a\u5173\u4e8e\u7b7e\u8ba2\u521b\u65b0\u836f\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f5c97489-4eb2-4e1c-84ad-a44aee2e500c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE: 002099) announced a strategic collaboration with Wanbangde New Building&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3818,24,1431,3819,732],"class_list":["post-53951","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hisoar-pharmaceutical","tag-rare-orphan-disease-drugs","tag-she-002082","tag-she-002099","tag-wanbangde-new-building-materials"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE: 002099) announced a strategic collaboration with Wanbangde New Building Materials Co., Ltd. (SHE: 002082) to co\u2011develop WP205, a small\u2011molecule cyclic peptide agonist for amyotrophic lateral sclerosis (ALS) that has received FDA Orphan Drug Designation. Hisoar will provide RMB\u202f150\u202fmillion (USD\u202f21.5\u202fmillion) in funding in exchange for 15\u202f% of global commercialization revenue.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53951\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE: 002099) announced a strategic collaboration with Wanbangde New Building Materials Co., Ltd. (SHE: 002082) to co\u2011develop WP205, a small\u2011molecule cyclic peptide agonist for amyotrophic lateral sclerosis (ALS) that has received FDA Orphan Drug Designation. Hisoar will provide RMB\u202f150\u202fmillion (USD\u202f21.5\u202fmillion) in funding in exchange for 15\u202f% of global commercialization revenue.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53951\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T13:11:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T13:11:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53951#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53951\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share\",\"datePublished\":\"2026-01-13T13:11:37+00:00\",\"dateModified\":\"2026-01-13T13:11:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53951\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Hisoar Pharmaceutical\",\"Rare \\\/ orphan disease drugs\",\"SHE: 002082\",\"SHE: 002099\",\"Wanbangde New Building Materials\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53951#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53951\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53951\",\"name\":\"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-13T13:11:37+00:00\",\"dateModified\":\"2026-01-13T13:11:38+00:00\",\"description\":\"Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE: 002099) announced a strategic collaboration with Wanbangde New Building Materials Co., Ltd. (SHE: 002082) to co\u2011develop WP205, a small\u2011molecule cyclic peptide agonist for amyotrophic lateral sclerosis (ALS) that has received FDA Orphan Drug Designation. Hisoar will provide RMB\u202f150\u202fmillion (USD\u202f21.5\u202fmillion) in funding in exchange for 15\u202f% of global commercialization revenue.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53951#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53951\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53951#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE: 002099) announced a strategic collaboration with Wanbangde New Building Materials Co., Ltd. (SHE: 002082) to co\u2011develop WP205, a small\u2011molecule cyclic peptide agonist for amyotrophic lateral sclerosis (ALS) that has received FDA Orphan Drug Designation. Hisoar will provide RMB\u202f150\u202fmillion (USD\u202f21.5\u202fmillion) in funding in exchange for 15\u202f% of global commercialization revenue.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53951","og_locale":"en_US","og_type":"article","og_title":"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share","og_description":"Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE: 002099) announced a strategic collaboration with Wanbangde New Building Materials Co., Ltd. (SHE: 002082) to co\u2011develop WP205, a small\u2011molecule cyclic peptide agonist for amyotrophic lateral sclerosis (ALS) that has received FDA Orphan Drug Designation. Hisoar will provide RMB\u202f150\u202fmillion (USD\u202f21.5\u202fmillion) in funding in exchange for 15\u202f% of global commercialization revenue.","og_url":"https:\/\/flcube.com\/?p=53951","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T13:11:37+00:00","article_modified_time":"2026-01-13T13:11:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53951#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53951"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share","datePublished":"2026-01-13T13:11:37+00:00","dateModified":"2026-01-13T13:11:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53951"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Hisoar Pharmaceutical","Rare \/ orphan disease drugs","SHE: 002082","SHE: 002099","Wanbangde New Building Materials"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53951#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53951","url":"https:\/\/flcube.com\/?p=53951","name":"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-13T13:11:37+00:00","dateModified":"2026-01-13T13:11:38+00:00","description":"Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE: 002099) announced a strategic collaboration with Wanbangde New Building Materials Co., Ltd. (SHE: 002082) to co\u2011develop WP205, a small\u2011molecule cyclic peptide agonist for amyotrophic lateral sclerosis (ALS) that has received FDA Orphan Drug Designation. Hisoar will provide RMB\u202f150\u202fmillion (USD\u202f21.5\u202fmillion) in funding in exchange for 15\u202f% of global commercialization revenue.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53951#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53951"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53951#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hisoar Pharma Invests RMB\u202f150\u202fMillion in Wanbangde\u2019s WP205 for ALS, Securing 15\u202f% Global Revenue Share"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53951"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53951\/revisions"}],"predecessor-version":[{"id":53954,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53951\/revisions\/53954"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}